UK markets close in 2 hours 53 minutes
  • FTSE 100

    7,517.10
    -4.29 (-0.06%)
     
  • FTSE 250

    18,968.95
    -131.13 (-0.69%)
     
  • AIM

    833.16
    -7.03 (-0.84%)
     
  • GBP/EUR

    1.1576
    -0.0008 (-0.07%)
     
  • GBP/USD

    1.2194
    +0.0061 (+0.50%)
     
  • BTC-GBP

    13,829.62
    -192.62 (-1.37%)
     
  • CMC Crypto 200

    395.77
    -6.03 (-1.50%)
     
  • S&P 500

    3,941.26
    -57.58 (-1.44%)
     
  • DOW

    33,596.34
    -350.76 (-1.03%)
     
  • CRUDE OIL

    75.03
    +0.78 (+1.05%)
     
  • GOLD FUTURES

    1,788.40
    +6.00 (+0.34%)
     
  • NIKKEI 225

    27,686.40
    -199.47 (-0.72%)
     
  • HANG SENG

    18,814.82
    -626.36 (-3.22%)
     
  • DAX

    14,285.23
    -57.96 (-0.40%)
     
  • CAC 40

    6,659.24
    -28.55 (-0.43%)
     

The past year for CureVac (NASDAQ:CVAC) investors has not been profitable

As every investor would know, you don't hit a homerun every time you swing. But it's not unreasonable to try to avoid truly shocking capital losses. It must have been painful to be a CureVac N.V. (NASDAQ:CVAC) shareholder over the last year, since the stock price plummeted 83% in that time. That'd be enough to make even the strongest stomachs churn. Because CureVac hasn't been listed for many years, the market is still learning about how the business performs. The falls have accelerated recently, with the share price down 32% in the last three months. We really hope anyone holding through that price crash has a diversified portfolio. Even when you lose money, you don't have to lose the lesson.

With that in mind, it's worth seeing if the company's underlying fundamentals have been the driver of long term performance, or if there are some discrepancies.

See our latest analysis for CureVac

CureVac wasn't profitable in the last twelve months, it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). Arguably revenue is our next best option. Shareholders of unprofitable companies usually expect strong revenue growth. That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.

In the last year CureVac saw its revenue grow by 164%. That's a strong result which is better than most other loss making companies. So the hefty 83% share price crash makes us think the company has somehow offended market participants. Something weird is definitely impacting the stock price; we'd venture the company has destroyed value somehow. What is clear is that the market is not judging the company on its revenue growth right now. Of course, investors do over-react when they are stressed out, so the sell-off could be unjustifiably severe.

The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).

earnings-and-revenue-growth
earnings-and-revenue-growth

We consider it positive that insiders have made significant purchases in the last year. Having said that, most people consider earnings and revenue growth trends to be a more meaningful guide to the business. You can see what analysts are predicting for CureVac in this interactive graph of future profit estimates.

A Different Perspective

CureVac shareholders are down 83% for the year, even worse than the market loss of 17%. There's no doubt that's a disappointment, but the stock may well have fared better in a stronger market. With the stock down 32% over the last three months, the market doesn't seem to believe that the company has solved all its problems. Given the relatively short history of this stock, we'd remain pretty wary until we see some strong business performance. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Case in point: We've spotted 2 warning signs for CureVac you should be aware of.

CureVac is not the only stock insiders are buying. So take a peek at this free list of growing companies with insider buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here